ENCY Encysive Pharmaceuticals (MM)

HOUSTON, Oct. 24 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that Bruce D. Given, M.D., President and Chief Executive Officer, will present a corporate overview at three upcoming health care conferences: the C.E. Unterberg, Towbin Life Sciences Conference; Rodman & Renshaw 8th Annual Healthcare Conference; and Cowen & Co. 7th Annual Global Health Care Conference. Encysive Pharmaceuticals' presentation schedule is as follows: * C.E. Unterberg, Towbin Life Sciences Conference - Tuesday, October 31 at 10 a.m. ET at The New York Palace Hotel, New York City. * Rodman & Renshaw 8th Annual Healthcare Conference - Monday, November 6 at 8:50 a.m. ET at The New York Palace Hotel. * Cowen & Co. 7th Annual Global Health Care Conference - Tuesday, November 7 at 5:30 p.m. GMT (12:30 p.m. ET), The Landmark Hotel, London. A live webcast of each presentation may be viewed on the Company's web site at http://www.encysive.com/. A replay will be available for 30 days following each respective presentation. About Encysive Pharmaceuticals Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com/. This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are our estimate of the sufficiency of our existing capital resources, our ability to raise additional capital to fund cash requirements for future operations, timelines for initiating new clinical trials, planned announcements of clinical data, the possibility of obtaining regulatory approval, our ability to manufacture and sell any products, potential drug candidates, their potential therapeutic effect, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate, our ability to discover new drugs in the future, and our ability to establish future collaborative arrangements. In particular, careful consideration should be given to cautionary statements made in the various reports Encysive, including as Texas Biotechnology Corporation, has filed with the Securities and Exchange Commission. Encysive undertakes no duty to update or revise these forward-looking statements. DATASOURCE: Encysive Pharmaceuticals CONTACT: Investors, Ann Tanabe, VP, Investor Relations and Corporate Communications of Encysive Pharmaceuticals, +1-713-796-8822; or Marcy Strickler of The Trout Group, +1-212-477-9007 ext. 27; or Media, Dan Budwick of BMC Communications, +1-212-477-9007 ext. 14, both for Encysive Pharmaceuticals Web site: http://www.encysive.com/

Copyright